Sign inJoin waitlistJoin the waitlist

HC

Hope Cottrill

Physician · H2 Health

Credentials: · · · · ·

History

H2 Health
2024–Present

University of Southern Florida
2009–2012
Obstetrics and Gynecology
University of Kentucky Hospital
2005–2009
University of Kentucky College of Medicine
1997–2001

Research

A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer
Review · Medical Oncology · 2017 · Last of 6 authors · 147 citations
BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival
Clinical Cancer Research · 2011 · 85 citations
Adverse impact of a history of violence for women with breast, cervical, endometrial, or ovarian cancer
Obstetrics and Gynecology · 2006 · 51 citations

Andrew Berchuck
3 papers
AP
Anil Potti
2 papers · 1 as a fellow
BO
Bryan Oronsky
2 papers
David Harpole
2 papers
Janiel Cragun
2 papers · 1 as a fellow
JB
John Barton
2 papers
Michael Kelley
2 papers
PF
Phillip Febbo
2 papers
Rebecca Petersen
2 papers · 2 as a fellow
Richard Riedel
2 papers
RS
Robyn Sayer
2 papers · 2 as a resident
Susan Modesitt
2 papers

Clinical trials

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2026–2028
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2031
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2034
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2022–2027